The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to investigate a complaint against Otsuka. The HJI has reported that the company is alleged to be engaging in exclusionary practices for the drug Delamanid. A hearing for the complaint has not been scheduled with the tribunal at this time.
top of page
Recent Posts
See AllA new study revealed that resistance is developing to the 6-month BPaLM regimen recommended by the WHO. The study investigated around...
Preliminary findings from the phase 1B PanACEA trial shows promising results for a new antibiotic, BTZ-043. The aim is to create an...
A new initiative in Nigeria aims to provide state health insurance to any patient with drug resistant TB in the country. Implementation...
bottom of page
Comments